Omar Abdihamid: I wonder if any study from Africa made it at ESMO2024
Nazik Hammad shared a post by Omar Abdihamid on X, adding:
“My thoughts: “Top Cancer Studies” that are mostly about drugs that will take forever and ever to get to 99% of African cancer patients, are not truly “top cancer studies”.”
Quoting Omar Abdihamid:
“Thoughts and reminders Amid all the “top cancer studies” presented at ESMO2024, Barcelona, I wonder if any study from Africa made it at The European Society for Medical Oncology (ESMO).
Access, disparity and equity to new science and drugs remain.”
Source: Omar Abdihamid/X and Nazik Hammad/X
Omar Abdihamid is a Cancer Research Fellow at Queen’s University and a Clinical Oncology Specialist at both the Garissa Cancer Center in Kenya and the HCGCCK Cancer Centre. Additionally, he serves as a Scientific Writer at MedSci Healthcare. His primary interests include culturally based cancer care, patient education, and cancer care advocacy.
Nazik Hammad is a Professor at the Division of Hematology and Oncology, St. Michael’s Hospital, University of Toronto. She was the Chair of the Education and Training Committee of the African Organization for Research and Training in Cancer (AORTIC). Dr. Hammad is a visiting professor at the University of Nairobi, Kenya. Her academic work and research interests include medical education and workforce development in low and middle-income countries (LMIC) particularly in sub-Saharan Africa.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023